Abstract 1703P
Background
More than 50% of new cancers are diagnosed in EP over the age of 70. The COVID-19 pandemic was particularly challenging for EP, which are the most fragile against both diseases. Telemedicine has clearly developed during this period but its place remains to be defined for EP. The ConnectPatientToDoctor study aimed to evaluate a connected telemonitoring platform, Haya by Cureety, for EP cancer care.
Methods
This prospective study was conducted at the Military Hospital Bégin on cancer patients aged ≥70 years. Patients were allowed to respond to a symptomatology questionnaire based on CTCAE v.5.0, personalized to their pathology and treatment. An algorithm evaluates the health status of the patient based on the reported adverse events, with a classification into four different states: - Correct (A) - Compromised (B) - State to be monitored (C) - Critical State (D). In case of A or B, the patient received therapeutic advice to help manage each of the reported adverse events. In the other states (C and D), the patient is invited to call the hospital. The primary endpoint was to assess the compliance of EP with the connected platform. The secondary endpoint was to assess patient’s satisfaction.
Results
Fifty-four patients were enrolled between July 1st, 2020 and March 31st, 2021. The median age was 78. 69% presented a metastatic stage, and the most represented cancer was prostate (69%). 70% were compliant and responded at the expected frequency (every 1 or 2 weeks). Overall, 1412 questionnaires were completed, resulting in 529 B-state and 145 C or D-state. More than 60% of the alerts were managed through outpatient care. 72% of the patients were satisfied.
Conclusions
EP had a clear benefit from using this platform. Patients felt less isolated and felt that they benefited from personalized care. This solution makes it possible to streamline the EP care process.
Table: 1703P
Patient characteristics
| Variables | N (%) |
| Number of patients | 54 |
| Median age (range) | 78 years (70-99) |
| Gender: Female, Male | 16 (29.6%), 38 (70.4%) |
| Location: Prostate, Lung, Breast, Other | 37 (68.5%), 6 (11.1%), 6 (11.1%), 5 (9.3%) |
| Stage: Localized, Metastatic, Other | 12 (22.2%), 37 (68.5%), 5 (9.3%) |
| Treatment: Chemotherapy, Hormonotherapy, Targeted therapy, Immunotherapy | 13 (24.1%), 32 (59.3%), 5 (9.3%), 4 (7.4%) |
| Patient included in a trial study | 20 (37.0%) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Helissey: Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: AstraZeneca. All other authors have declared no conflicts of interest.